Phase 3 results for the Novartis malaria drug “GanLum” show it was comparable to the standard of care and led to cure rates that top the threshold recommended by the World Health Organization. If approved, this new combination drug would become the first novel malaria therapy in more than 25 years.
The post Novel Novartis Malaria Drug Shows Promise to Become New Asset Against Resistant Strains appeared first on MedCity News.
CISA Flags Critical WatchGuard Fireware Flaw Exposing 54,000 Fireboxes to No-Login Attacks
The U.S. Cybersecurity and Infrastructure Security Agency (CISA) on Wednesday added a critical security flaw impacting WatchGuard Fireware to its Known Exploited Vulnerabilities (KEV) catalog,
